Paper · 28416604
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Karkera JD and 13 others. Mol Cancer Ther, 2017. Cited by 49 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Papers, record 28416604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28416604
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oncogenes | Major topic |
| Pyrazoles | Major topic |
| Quinoxalines | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Animals | |
| Biomarkers, Tumor | |
| Male | |
| Oncogene Proteins, Fusion | |
| Rats, Nude | |
| Tomography, X-Ray Computed | |
| Urinary Bladder Neoplasms |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,124,891 | Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression. | Bladder Cancer | 2026 | https://conductscience.org/library/papers/42124891 | PubMed |
| 41,804,750 | Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/41804750 | PubMed |
| 41,487,403 | Molecular mechanisms of human papillomavirus-induced tongue carcinogenesis: A systematic review. | J Oral Biol Craniofac Res | 2026 | https://conductscience.org/library/papers/41487403 | PubMed |
| 41,125,751 | Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling. | Sci Rep | 2025 | https://conductscience.org/library/papers/41125751 | PubMed |
| 40,001,320 | A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40001320 | PubMed |
| 39,001,460 | Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39001460 | PubMed |
| 38,710,951 | Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38710951 | PubMed |
| 37,980,453 | Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. | Sci Rep | 2023 | https://conductscience.org/library/papers/37980453 | PubMed |
| 37,889,382 | Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. | Invest New Drugs | 2023 | https://conductscience.org/library/papers/37889382 | PubMed |
| 36,551,764 | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. | Biomedicines | 2022 | https://conductscience.org/library/papers/36551764 | PubMed |
1 to 10 of 32
See all 32 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| TACC3 | 10,460 | PubTator's text mining | https://conductscience.org/library/genes/10460 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28416604
GET https://conductscience.org/api/papers/v1/28416604/cited_by?page=2